1650-g vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00654030)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanoma cellsImmunity, active
immunity, active - melanoma cells
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1650-g vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00654030 | Phase 2 | Oct 1, 2006 | Commonwealth Cancer Center, Kentucky Lung Cancer Research Program, Owensboro Medical Health System, University of Kentucky, University of Louisville |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Commonwealth Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Kentucky Lung Cancer Research Program | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Owensboro Medical Health System | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Kentucky | Academic/Hospital | 1 | 1 | 1 | 2006 |
| University of Louisville | Academic/Hospital | 1 | 0 | 1 | 2006 |
5 organizations
Page 1 / 1